Companies / NSB

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

ASX:NSBPharmaceuticals, Biotechnology & Life Sciences
389.7M shares on issueASX (delayed) · as of 28 July 2026$0.064price · delayed$25.3Mmarket cap · indicative
C
Dilution grade

Share count grew 59% in 24 months; runway 2–4 quarters; 2 cash raises in 24 months

Cash runway3.8 quarters of funding
Share-count growth (24m)59.3%
Raise cadence (24m)2 cash raises
Options & rights overhang11.5% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD's ordinary share count grew 59.3% between June 2025 and June 2026, to 390M shares. The company raised capital twice in that 24‑month window for total disclosed proceeds of A$7.0M, most recently a A$3.5M placement in June 2025. Options and rights on issue could convert into 45M new shares, equal to 11.5% of the current share count, with 0% in the money at the current share price; the nearest expiry is June 2027. At the June 2026 quarter the company reported A$4.3M in available cash, about 3.8 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
11.5%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
3.8 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 389.7M per ASX (delayed) (28 July 2026).
196.1M267.2M338.2MDec 24Sept 25July 26Cash raise · 27 June 2025Cash raise · 11 Apr 2025

Cash runway

3.8 qtrs
Two to four quarters of funding at the recent spend rate.
$4.3M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
30 June 20263H · cancellationNSB : ORDINARY FULLY PAID389.7MAppendix 3H
1 June 20262A · quoted issueNSB : ORDINARY FULLY PAID389.7MAppendix 2A
15 Sept 20253G · unquotedNSB : ORDINARY FULLY PAID332.6MAppendix 3G
26 June 20253G · unquotedNSB : ORDINARY FULLY PAID144.6MAppendix 3G
26 June 20252A · quoted issueNSB : ORDINARY FULLY PAID146.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 0 in the last 12 months

$3.5M
Placement
27 June 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

11.5%
Total overhang · of current shares
0.0%
In the money · at current price
44.8M
Potential new shares
June 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 June 2026Robert Leslie McKenzieOther3.9M5.0M—3Y notice
1 June 2026Paul Damien John FryOther9.0M5.0M—3Y notice
27 June 2025Dr Anton UvarovOther2.4M1.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
21 July 2026StemSmart Presentation - ISCT ANZ 2026
30 June 2026Notification of cessation of securities - NSB
19 June 2026Escrowed Securities Update
11 June 2026Investor Webinar
8 June 2026Change in substantial holding
3 June 2026Becoming a substantial holder
2 June 2026Change of Director's Interest Notice x2
1 June 2026Section 708A Notice
1 June 2026Application for quotation of securities - NSB
26 May 2026Updated Presentation - Successful Results
25 May 2026$PRemarkable Results from Patients treated with StemSmart
24 May 2026$PTrading Halt
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
16 Mar 2026StemSmart Manufacturing Scale-Up Transfer Advances
25 Feb 2026$PHalf Yearly Report and Accounts
15 Feb 2026Company Presentation
29 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
12 Jan 2026$PSuccessful Clinical Results Achieved under Special Access
8 Jan 2026$PTrading Halt

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.